GE provides Merck with imaging agent for Alzheimer's drug trial
This article was originally published in Scrip
Executive Summary
GE Healthcare is to provide its investigational amyloid imaging agent 18F flutemetamol to Merck for use in a Phase II/III trial of the latter's lead Alzheimer's disease drug candidate, MK-8931.